Cannabis and mental health: Management in primary care

Australian Family Physician

Volumn 39, Issue 8, 2010, Pages 554-557

  Lubman, Dan I ^a   Baker, Amanda ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Cannabis; General practice; Mental health; Substance related disorders

Indexed keywords

ARTICLE; AUSTRALIA; CANNABIS ADDICTION; COGNITIVE THERAPY; DEPRESSION; HUMAN; PRIMARY HEALTH CARE; PSYCHOLOGICAL ASPECT; PSYCHOSIS;

AUSTRALIA; COGNITIVE THERAPY; DEPRESSION; HUMANS; MARIJUANA ABUSE; PRIMARY HEALTH CARE; PSYCHOTIC DISORDERS;

EID: 77957314527     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Australian Institute of Health and Welfare. 2007 National Drug Strategy Household Survey: detailed findings. Drug statistics series no. Cat. No.22 PHE 107. Canberra: AIHW, 2008.
2. Degenhardt L, Lynskey M, Hall W. Cohort trends in the age of initiation of drug use in Australia. Aust N Z J Public Health 2000;24:421-6.
3. Hall WD. Cannabis use and the mental health of young people. Aust N Z J Psychiatry 2006;40:105-13.
4. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39:421-9.
5. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008;192:306-7.
6. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999;58:315-48.
7. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol 2004;29:1558-72.
8. Yücel M, Solowij N, Respondek C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008;65:694-701.
9. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-28.
10. Frisher M, Crome I, Martino O, Croft P. Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005Schizophr Res 2009;113:123-8.
11. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005;112:141-8.
12. Patton GC, Coffey C, Carlin JB, et al. Cannabis use and mental health in young people: cohort study. BMJ 2002;325:1195-8.
13. Hides L, Lubman DI, Cosgrave EM, Buckby JA, Killackey E, Yung AR. Motives for substance use among young people seeking mental health treatment. Early Intervention in Psychiatry 2008;2:188-94.
14. Baker K, Lubman DI, Cosgrave EM, et al. The impact of co-occurring substance use on six-month outcomes for young people seeking mental health treatment. Aust N Z J Psychiatry 2007;41:896-902.
15. Carroll S, Hides L, Catania L, Mathias S, Greenwood-Smith C, Lubman DI. Integrated cognitive behaviour therapy (CBT) for co-occurring substance misuse and major depression: Lessons from a youth mental health service. Australas Psychiatry 2009;5:365-70.
16. Hides L, Carroll S, Catania L, et al. Integrated cognitive behaviour therapy (CBT) for co-occurring depression and substance misuse in young people: a pilot study. J Affect Disord 2010;121:169-74.
17. Banerjee S, Clancy C, Crome I. Co-existing problems of mental disorder and substance misuse (dual diagnosis). London: Royal College of Psychiatrists Research Unit, 2002.
18. Mueser KT, Yarnold P, Bellack AS. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand 1992;85:48-55.
19. Lampropoulos B. Substance abuse and harm minimisation in adolescents. Aust Fam Physician 2007;30:602-4.
20. Goldenbring JM, Cohen E. Getting into adolescent HEADS. Contemp Pediatr 1988;7:75-90.
21. Velleman R. Co-existing problems: from conceptualization to case formulation. In: Baker A, Velleman R, editors. Clinical handbook of co-existing mental health and drug and alcohol problems. London: Routledge, 2007:20-38.
22. Jablensky A, McGrath J, Herrman H, et al. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Aust N Z J Psychiatry 2000;34:221-36.
23. Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population prevalence and trends in non-specific psychological distress. Psychol Med 2002;32:959-6.
24. Lee N, Jenner L, Kay-Lambkin F, et al. PsyCheck: responding to mental health issues within alcohol and drug treatment. Canberra: Commonwealth of Australia, 2007.
25. Beusenberg M, Orley J. User's guide to the Self Reporting Questionnaire. Geneva: World Health Organization, 1994.
26. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Development, reliability and feasibility. Addiction 2002;97:1183-94.
27. Gossop M, Darke S, Griffiths P, et al. The Severity of Dependence Scale (SDS): Psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995;90:607-14.
28. Adamson S, Kay-Lambkin F, Baker A, et al. An improved brief measure of cannabis misuse: The Cannabis Use Disorders Identification Test - Revised (CUDIT-R). Drug Alcohol Depend 2010;110:137-43.
29. Miller WR, Rollnick S. Motivational interviewing: preparing people to change addictive behaviour. 2nd edn. New York: Guilford Press, 2002.
30. Rollnick S, Mason P, Butler C. Health behaviour change: a guide for practitioners. Edinburgh: Churchill Livingstone, 1999.
31. Baker A, Hides L, Lubman DI. Treatment of cannabis use among people with psychotic and depressive disorders: a systematic review. J Clin Psychiatry 2010;71:247-54.
32. Kay-Lambkin FJ, Baker A, Lewin TJ, Carr VJ. Computer-based psychological treatment for comorbid depression and substance use problems: a randomised controlled trial of clinical efficacy. Addiction 2009;104:378-88.
33. Barrowclough C, Haddock G, Tarrier N, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001;158:1706-13.
34. Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Carr VJ, Constable P. Cognitive-behavioural therapy for substance use disorders among people with psychotic disorders: randomised controlled trial. Br J Psychiatry 2006;188:439-48.
35. Lubman DI, Sundram S. Substance use in patients with schizophrenia: a primary care guide. Med J Aust 2003;178:S71-5.